Menu ×

HEALTHCARE & PHARMACEUTICAL

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Segmentation by Therapy Type (Chemotherapy, Immunotherapy, Radiotherapy, Hormonal Therapy, and Others); and by Application (General Medical & Surgical Hospitals, Speciality Hospitals, Clinics, and Others) – Global Demand Analysis and Opportunity Outlook 2021-2029

  • Text Size:

Extensive insights into the Growth of Non-Metastatic Castration Resistant Prostate Cancer Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Highlights 2020-2029

The non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. Extensive research associated with cancer treatment in western countries, along with the growing investment in the development of advanced therapies are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and the rising prevalence of nmCRPC amongst individuals on a global level. According to the data collected from National Cancer Institute of the U.S. Department of Health and Human Services, in 2020, the estimated new cases and number of deaths from prostate cancer in the U.S. were 191,930 and 33,330, respectively.

nmCRPC Treatment

The market is segmented based on therapy type into chemotherapy, immunotherapy, radiotherapy, hormonal therapy, and others, out of which, the hormonal therapy segment is anticipated to grab the largest share by the end of 2021 on account of higher positive diagnosis rates and better efficiency of hormonal therapy than chemotherapy. Moreover, hormonal therapy is widely being used as an adjuvant treatment alongside radiation therapy and surgery, which is also projected to contribute to the growth of the segment during the forecast period.

On the basis of application, the speciality hospitals segment in the global nmCRPC treatment market is projected to grow with significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that nmCRPC is a relatively rare occurrence and as a result, a considerable portion of the population with this cancer on a global level tend to choose healthcare facilities specializing in its treatment. CLICK TO DOWNLOAD SAMPLE REPORT

Non-Metastatic Castration Resistant Prostate Cancer Treatment Market Regional Synopsis

Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in cancer research, accompanied by the presence of leading healthcare service providers in the region. Along with this, the North America also leads in terms of ongoing clinical trials, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the mnCRPC treatment market on account of its proven success in terms of drug development and a high prevalence of prostate cancer in the region. As per the analysis of European Commission, prostate cancer is ranked first among the most widely diagnosed cancer among men in the European Union.

The global non-metastatic castration resistant prostate cancer treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global non-metastatic castration resistant prostate cancer market includes the following segments:

By Therapy Type

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Hormonal Therapy
  • Others

By Application

  • General Medical & Surgical Hospitals
  • Specialty Hospitals
  • Clinics
  • Others

Growth Drivers

  • Rising Prevalence of Prostate Cancer
  • Increasing Geriatric Population in the World

Challenges

  • Expensive nmCRPC Treatment Therapies
  • Lack of Awareness About the Disease in Lower Economic Regions

Top Featured Companies Dominating the Market

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved